Readit News logoReadit News
ReptileMan · 2 months ago
Somewhat irrelevant at this point. The peptides are sold freely in other countries as substances with which to experiment in petri dishes. Not for use on humans. I repeat - not for use on humans.
vitorgrs · 2 months ago
It's relevant in Brazil because it's already announced the public health care system will distribute for free.
diath · 2 months ago
These days people just order Reta/Triz instead of Sema off steroid websites anyway, so the patent is not a big deal.
GenerWork · 2 months ago
I'm not saying I've done this, but if you're handy with bitcoin, it's so much cheaper to go through the steroid sites. I saw a sale of 10 x 10mg for reta where the total price was $225 with shipping. That's $22.5 per vial which is absurdly cheaper than any of the "legit" methods of getting GLPs.

And hey, if you want a little test/anavar/tren to spice up your GLP, you can get that in the same order!

aitchnyu · 2 months ago
Did I get it right Triz (Mounjaro or Zepbound) and Reta (still in clinical trials) have better mechanisms than Sema (Ozempic or Wegovy), so gray market customers choose them, and gray market versions of all three are a fraction of official versions?
andrewinardeer · 2 months ago
Counterfeits is a problem. How would you know you are getting the real deal?
dervjd · 2 months ago
Would be interested to know more about which website you saw the sale on. For research purposes of course, have my email in bio.
KumaBear · 2 months ago
Actually all the mom groups in Facebook started bulk buying as well it’s insane the gray market that was made by there pricing in the US
asdff · 2 months ago
The worst thing about these drugs hitting the pharma market in recent years is that it has sucked the air out of the room for other investment due to their immense profitability. So much cutting edge talent is being squandered to work on these weight loss drugs because they pay the bills better than solving rare disease. I've heard a direct quote from a pharma product manager in person: "we don't look for cures, we look for treatments." You know, because cure implies a one time payment.

Talk about perverse incentive.

Waterluvian · 2 months ago
> So much cutting edge talent is being squandered to work on these weight loss drugs because they pay the bills better than solving rare disease.

Isn’t this backwards? Obesity is probably one of the very top health epidemics we’re facing. Rare diseases aren’t.

Deleted Comment

asdff · 2 months ago
Weight loss is solved already. Diet and exercise. Done. No profit for pharma company doing that though.

Rare diseases are not solved, you die or have lifelong quality of life issues. Collectively, they aren't that rare.

0cf8612b2e1e · 2 months ago
Yeah, the top talent should focus on finding better ways to monetize ads, not a health issue impacting hundreds of millions of people.
diath · 2 months ago
The problem is that this talent is not solving the issue. They're creating appetite suppressants to treat the symptoms of the underlying issue. We should be implementing things like sugar tax instead. Starbucks has no business selling 1500 calories worth of sugar with a sprinkle of coffee in a cup.
jryb · 2 months ago
I’m not so sure. When pharma companies are flush with cash they tend to get more experimental. Lilly’s gene editing group is one of the few that’s doing well (last I heard anyway) and they recently acquired Verve. I can’t imagine that would happen without GLP-1 profits bankrolling everything. Rare disease is effectively charity and the money has to come from somewhere.